February 10, 2023 – Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Share on Pinterest UCLA researchers recently found that PSA levels after prostate cancer treatment may not be the best indicator of survival. andresr/Getty Images A new study from UCLA researchers ...

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...

Dye binds to proteins altered by prostate cancer fo form PSA. Two of the most commonly used classes of medication—statins and nonsteroidal anti-inflammatory drugs (NSAIDs)—may compromise already ...

Deep prostate-specific antigen (PSA) response, defined as a ≥90% decline in PSA (PSA90), is an important early prognostic factor for achieving radiographic progression-free survival and overall ...

Men with metastatic hormone-sensitive prostate cancer treated with Nubeqa, androgen-deprivation therapy and docetaxel had reductions in PSA levels that were associated with improved overall survival ...

(CHICAGO) -- A dietary supplement containing genistein, a soy extract, reduced PSA levels by as much as 61 percent in a group of prostate cancer patients undergoing "watchful waiting" for their ...